Emmaus Life Sciences has announced the allowance of patent application number 12860587.0, directed to the treatment of diverticulosis, by the European Patent Office.
Emmaus Life Sciences announced the screening of the first patient for the company's Pilot/Phase 1 study on the treatment of diverticulosis with pharmaceutical-grade L-glutamine (PGLG).